Literature DB >> 16943228

Supplementation of CD4+CD25+ regulatory T cells suppresses experimental autoimmune uveoretinitis.

H Keino1, M Takeuchi, Y Usui, T Hattori, N Yamakawa, T Kezuka, J-I Sakai, M Usui.   

Abstract

AIMS: To investigate whether supplementation of natural CD4+CD25+ regulatory T cells ameliorates mouse experimental autoimmune uveoretinitis (EAU) induced by CD4+ T cell-dependent interphotoreceptor retinoid-binding protein (IRBP).
METHODS: C57BL/6 mice were immunised with human interphotoreceptor retinoid-binding protein peptide 1-20 (IRBP(1-20)), and IRBP(1-20)-sensitised T cells were obtained. CD4+CD25+ T cells derived from naive mice were cocultured with IRBP(1-20)-sensitised T cells, and their proliferation responses and cytokine production were measured. In addition, CD4+CD25+ T cells were transferred intravenously into mice 7 or 15 days after immunisation with IRBP(1-20), and the severity of EAU and T cell proliferation responses were evaluated.
RESULTS: CD4+CD25+ regulatory T cells effectively inhibited both the proliferation of, and interleukin (IL)2, IL5 and interferon (IFN)gamma production by, IRBP(1-20)-sensitised T cells. Adoptive transfer of CD4+CD25+ regulatory T cells to IRBP(1-20)-immunised mice conferred considerable protection from EAU development and inhibition of T cell proliferation responses to IRBP(1-20).
CONCLUSION: These findings show that natural CD4+CD25+ regulatory T cells possess the ability to inhibit activation of IRBP-reactive T cells that have been already sensitised in vivo, and adoptive transfer of these cells ameliorates EAU even in the effector phase. Supplementation of natural CD4+CD25+ regulatory T cells may have therapeutic potential for effective treatment of uveitis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16943228      PMCID: PMC1857594          DOI: 10.1136/bjo.2006.099192

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  26 in total

1.  Oral tolerance in a murine model of relapsing experimental autoimmune uveoretinitis (EAU): induction of protective tolerance in primed animals.

Authors:  S R Thurau; C C Chan; R B Nussenblatt; R R Caspi
Journal:  Clin Exp Immunol       Date:  1997-08       Impact factor: 4.330

2.  Pathology of experimental autoimmune uveoretinitis in mice.

Authors:  C C Chan; R R Caspi; M Ni; W C Leake; B Wiggert; G J Chader; R B Nussenblatt
Journal:  J Autoimmun       Date:  1990-06       Impact factor: 7.094

3.  A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens.

Authors:  R R Caspi; F G Roberge; C C Chan; B Wiggert; G J Chader; L A Rozenszajn; Z Lando; R B Nussenblatt
Journal:  J Immunol       Date:  1988-03-01       Impact factor: 5.422

4.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.

Authors:  S Sakaguchi; N Sakaguchi; M Asano; M Itoh; M Toda
Journal:  J Immunol       Date:  1995-08-01       Impact factor: 5.422

Review 5.  Unresponsiveness to self-peptides of S-antigen in EAU: an overview of recent results.

Authors:  D S Gregerson; S P Fling; L A Donoso; D P Gold
Journal:  Curr Eye Res       Date:  1992       Impact factor: 2.424

6.  Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state.

Authors:  T Takahashi; Y Kuniyasu; M Toda; N Sakaguchi; M Itoh; M Iwata; J Shimizu; S Sakaguchi
Journal:  Int Immunol       Date:  1998-12       Impact factor: 4.823

7.  Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis.

Authors:  Adam P Kohm; Pamela A Carpentier; Holly A Anger; Stephen D Miller
Journal:  J Immunol       Date:  2002-11-01       Impact factor: 5.422

8.  Immune responses to retinal self-antigens in CD25(+)CD4(+) regulatory T-cell-depleted mice.

Authors:  Masaru Takeuchi; Hiroshi Keino; Takeshi Kezuka; Masahiko Usui; Osamu Taguchi
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-06       Impact factor: 4.799

9.  Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta.

Authors:  K Nakamura; A Kitani; W Strober
Journal:  J Exp Med       Date:  2001-09-03       Impact factor: 14.307

10.  An immunologically privileged retinal antigen elicits tolerance: major role for central selection mechanisms.

Authors:  Dody Avichezer; Rafael S Grajewski; Chi-Chao Chan; Mary J Mattapallil; Phyllis B Silver; James A Raber; Gregory I Liou; Barbara Wiggert; Giavonni M Lewis; Larry A Donoso; Rachel R Caspi
Journal:  J Exp Med       Date:  2003-12-01       Impact factor: 14.307

View more
  14 in total

Review 1.  Autoimmune uveitis: clinical, pathogenetic, and therapeutic features.

Authors:  Marcella Prete; Rosanna Dammacco; Maria Celeste Fatone; Vito Racanelli
Journal:  Clin Exp Med       Date:  2015-03-28       Impact factor: 3.984

2.  Everolimus for the treatment of uveitis refractory to cyclosporine A: a pilot study.

Authors:  Arnd Heiligenhaus; Beatrix Zurek-Imhoff; Martin Roesel; Maren Hennig; Daniela Rammrath; Carsten Heinz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-10-17       Impact factor: 3.117

3.  Ocular regulatory T cells distinguish monophasic from recurrent autoimmune uveitis.

Authors:  Yan Ke; Guomin Jiang; Deming Sun; Henry J Kaplan; Hui Shao
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-05-16       Impact factor: 4.799

4.  CD4+Foxp3+ T-regulatory cells in noninfectious uveitis.

Authors:  Steven Yeh; Zhuqing Li; Farzin Forooghian; Frank S Hwang; Matthew A Cunningham; Seth Pantanelli; Julie C Lew; Keith K Wroblewski; Susan Vitale; Robert B Nussenblatt
Journal:  Arch Ophthalmol       Date:  2009-04

5.  c-Rel is Required for the Induction of pTregs in the Eye but Not in the Gut Mucosa.

Authors:  Ting Wang; Weiyun Shi; Tingting Fan; Xiaochun Wan; Youhai H Chen; Qingguo Ruan
Journal:  Immunol Invest       Date:  2016-05-25       Impact factor: 3.657

6.  Mediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside transporter and A2A adenosine receptor.

Authors:  Gregory I Liou; John A Auchampach; Cecilia J Hillard; Gu Zhu; Bilal Yousufzai; Salman Mian; Sohail Khan; Yousuf Khalifa
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-07-18       Impact factor: 4.799

7.  Aminoimidazole carboxamide ribonucleotide ameliorates experimental autoimmune uveitis.

Authors:  Jun Suzuki; Takeru Yoshimura; Marina Simeonova; Kimio Takeuchi; Yusuke Murakami; Yuki Morizane; Joan W Miller; Lucia Sobrin; Demetrios G Vavvas
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-06-28       Impact factor: 4.799

8.  Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis.

Authors:  Lili Mu; Bo Sun; Qingfei Kong; Jinghua Wang; Guangyou Wang; Shujuan Zhang; Dandan Wang; Yumei Liu; Yixi Liu; Huixia An; Hulun Li
Journal:  Immunology       Date:  2009-03-23       Impact factor: 7.397

9.  Updates on the risk markers and outcomes of severe juvenile idiopathic arthritis-associated uveitis.

Authors:  Sheila T Angeles-Han; Steven Yeh; Larry B Vogler
Journal:  Int J Clin Rheumtol       Date:  2013-02-01

10.  Evaluation of the IL2/IL21, IL2RA and IL2RB genetic variants influence on the endogenous non-anterior uveitis genetic predisposition.

Authors:  María Carmen Cénit; Ana Márquez; Miguel Cordero-Coma; Alejandro Fonollosa; Alfredo Adán; Agustín Martínez-Berriotxoa; Victor Llorenç; David Díaz Valle; Ricardo Blanco; Joaquín Cañal; Manuel Díaz-Llopis; José Luis García Serrano; Enrique de Ramón; María José del Rio; Marina Begoña Gorroño-Echebarría; José Manuel Martín-Villa; Norberto Ortego-Centeno; Javier Martín
Journal:  BMC Med Genet       Date:  2013-05-15       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.